Methylphenidate hydrochloride: salt form of methylphenidate

Methylphenidate hydrochloride is the salt form of methylphenidate used in medicines. Hydrochloride formation improves the water solubility, stability and bioavailability of free methylphenidate base and is the basis of numerous products (Ritalin, Medikinet, Concerta, Equasym, Kinecteen). Pharmacologically methylphenidate hydrochloride is identical with methylphenidate: in the body the salt dissociates and the active drug exerts its central nervous system effect.

Methylphenidate is subject to the German narcotic prescription regulation (BtMVV) and may only be prescribed on a narcotic prescription. The main indication is attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults, as well as narcolepsy.

Mechanism of action

Methylphenidate is a central stimulant of the phenethylamine class. The D-threo enantiomer (dexmethylphenidate) is the main active form. The substance inhibits the dopamine and noradrenaline reuptake transporters (DAT and NET) in presynaptic neurons of the prefrontal cortex and striatum, without producing the massive vesicular release of these transmitters seen with amphetamines.

Increased synaptic availability of dopamine and noradrenaline optimises fronto-striatal signalling. Clinically this leads to better concentration, attention, impulse control and working memory performance. In ADHD, mood regulation and the ability to structure tasks often improve as well.

The effect starts about 30 to 60 minutes after oral intake. Duration of action depends on the formulation: immediate-release methylphenidate works for 3 to 5 hours, sustained-release products (Concerta, Medikinet retard, Equasym XL) cover 6 to 12 hours.

Indications

• Attention deficit hyperactivity disorder (ADHD): as part of a comprehensive treatment plan in children from 6 years, adolescents and adults, when non-pharmacological measures are not enough
• Narcolepsy: when other therapies are insufficient
• Off-label: fatigue in palliative care, post-stroke apathy

Important: methylphenidate is not indicated for cognitive enhancement in healthy individuals. Off-label use as a cognitive enhancer is medically unjustified and carries risks.

Dosing and administration

Children from 6 years and adolescents: starting dose 5 mg once or twice daily, titrated by 5 to 10 mg per week to clinical effect. Usual maintenance 0.3 to 1 mg per kg per day, maximum 60 mg per day with immediate-release products, 72 mg with Concerta.

Adults: starting dose 10 mg in the morning, titrated by 10 mg per week, usual maintenance 20 to 60 mg per day.

Intake is in the morning or before noon. Later doses may impair sleep. Sustained-release tablets are swallowed whole; some products (Medikinet retard, Equasym XL) can be opened and stirred into apple sauce or yoghurt for patients with swallowing problems.

Drug holidays: regular review of ongoing need; in children at least annual treatment breaks are recommended.

Side effects

Very common: insomnia, decreased appetite, headache, nervousness, mild nausea, dry mouth.

Common: abdominal pain, mood changes, mild tachycardia, raised blood pressure, weight loss, mild growth slowing in children.

Uncommon: tics or worsening of pre-existing tics, hallucinations, paranoia, panic attacks, sweating, pruritus, rash.

Rare and very rare: cardiac events (especially with pre-existing structural anomalies), cerebrovascular events, severe depression with suicidality, priapism, erythema multiforme, Stevens Johnson syndrome, leukopenia, vasculitis, Raynaud's phenomenon.

Important aspects for patients and parents:

• Growth monitoring (height, weight) in children every six months
• Blood pressure and pulse before therapy and during follow-up
• Sudden chest pain or syncope warrants prompt medical evaluation
• Personality changes, new aggression or mood drop should prompt consultation
• Substance use history (also in the family) should be enquired about, given the misuse potential

Interactions

• MAO inhibitors (tranylcypromine, moclobemide): hypertensive crisis, combination contraindicated; minimum 14 days after stopping an MAO inhibitor
• Tricyclic antidepressants, SSRIs: raised levels, careful titration
• Vasopressors, adrenergics: additive blood pressure rise
• Sympathomimetics in cold remedies (pseudoephedrine): caution
• Anticoagulants (warfarin, phenprocoumon): possible enhancement, monitor INR
• Antiepileptics (phenytoin, phenobarbital, primidone): level changes, monitoring useful
• Alcohol: influences release from sustained-release galenics (alcoholic dose dumping reduced for Concerta), plus additive CNS effects

Special considerations

Pregnancy: not recommended, avoid in the first trimester where possible. Data suggest a slightly increased risk of malformations, especially heart defects.

Breastfeeding: small amounts pass into milk, individual evaluation; acceptable at low dose.

Before starting therapy:

• History of cardiac disease, sudden cardiac death in family, cardiac symptoms
• Blood pressure and pulse check, ECG if abnormalities
• Psychiatric history (psychosis, bipolar disorder, substance use history)
• Tic disorders or Tourette syndrome in the family
• Glaucoma, phaeochromocytoma, hyperthyroidism

Contraindications: known severe heart disease, severe hypertension, hyperthyroidism, phaeochromocytoma, narrow-angle glaucoma, advanced atherosclerosis, manic episode, acute Tourette syndrome, concomitant MAO inhibitors.

Misuse potential: methylphenidate has misuse potential, particularly at higher doses and with non-oral use. At therapeutic doses with controlled prescribing, the risk is small. Parents should keep tablets safely.

Related substances

• Lisdexamfetamin, prodrug stimulant for ADHD
• Lisdexamfetamine, English spelling
• Atomoxetin, non-stimulant ADHD therapy
• Buspirone, anxiolytic for comorbid disorder

Frequently asked questions

Sources

• BfArM Federal Institute for Drugs and Medical Devices
• EMA European Medicines Agency
• AWMF S3 guideline ADHD
• Gelbe Liste methylphenidate monograph